Study of Suramin in Subjects With Furosemide-Resistant AKI

PHASE2UnknownINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

April 17, 2023

Study Completion Date

December 22, 2023

Conditions
Acute Kidney Injury
Interventions
DRUG

Suramin

Suramin is administered via IV infusion as a single dose of 3 mg/kg

DRUG

Placebo

Placebo

Trial Locations (12)

11355

New York-Presbyterian Medical Center of Queens, Flushing

30097

Emory Johns Creek Hospital, Johns Creek

30303

Emory University School of Medicine, Atlanta

37404

Southeast Renal Research Institute, Chattanooga

40536

University of Kentucky, Lexington

65212

University of Missouri - Dept. of Surgery, Columbia

72205

University of Arkansas Medical Sciences (UAMS), Little Rock

75246

Baylor Scott and White Research Institute - Dallas Clinical Trials Office, Dallas

87131

University of New Mexico Health Science Center, Albuquerque

91942

California Institute of Renal Research, La Mesa

900953

Ronald Reagan UCLA Medical Center, Los Angeles

27157-1009

Wake Forest Baptist Medical Center, Winston-Salem

Sponsors
All Listed Sponsors
lead

Rediscovery Life Sciences

INDUSTRY